An assessment of conformance to structured reporting framework in 68 Ga prostate-specific membrane antigen PET/computed tomography for prostate cancer staging.

Background68 Ga prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) plays a critical role in prostate cancer management. Most clinical reports, however, remain unstructured, increasing the risk of omitting essential diagnostic information. Although standardized frameworks such as PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) have been proposed to improve consistency, real-world adherence remains variable. This study assessed the adequacy of 68 Ga PSMA PET/CT reports and evaluated their alignment with PROMISE recommendations.MethodsA total of 189 68 Ga PSMA PET/CT reports were retrospectively reviewed and scored based on the presence (1) or absence (0) of six diagnostic elements: primary tumor localization, PSMA uptake intensity, lymph node involvement, bone metastases, visceral metastases, and seminal vesicle involvement. Reports were classified as clinically adequate (score ≥5), partially adequate (3-4), or inadequate (